InsidersTradesSigma
삼익제약 Stock: price and directors' dealings · South Korea · DART (FSS)
Follow the 삼익제약 share price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares trade on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 삼익제약 has published 5 insider filings. Market capitalisation: €41.1bn. The latest transaction was filed on 25 June 2026 (Sale). Among the most active insiders: 권영이. All data is free.
5
Insider Decl.
n/a
Thresholds
€76,464
1 ops.
Buy Volume
€89,675
4 ops.
Sell Volume
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,236 of 27,989 companies
33.8
score / 100
Value22
Quality46
FCF yld-3.3%
Earn yld-1.8%
EV/EBITDA30.4x
ROE-1.2%
Gross mgn71%
Net mgn-1.3%
Debt/EBITDA2.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 25 June 2026
Declarations5 total
5 of 5 declarations
About 삼익제약
Samik Pharmaceutical is a company in the health and pharmaceutical sector, listed on the XKRX exchange. It focuses on the development and production of drugs and pharmaceutical products.